PDF
Full
Outline
Narsoplimab was first approved by the U.S. Food and Drug Administration (FDA) on December 24,2025, for the management of thrombotic microangiopathy following hematopoietic stem cell transplantation (TA-TMA) in children aged 2 years and older and adults. As a serious complication of hematopoietic stem cell transplantation (HSCT), TA-TMA is characterized by high mortality. TA-TMA is associated with endothelial injury and can activate the complement agglutinin pathway, where mannose-binding agglutinin-related serine protease-2 (MASP-2) is a key enzyme. Narsoplimab is a humanized monoclonal antibody that specifically binds to and inhibits MASP-2, thereby reducing complement activation in damaged tissues without compromising the beneficial role of complement in anti-infection. Multiple real-world studies have demonstrated a high response rate. This article provides an overview of the mechanism of action, pharmacodynamics, pharmacokinetics, clinical studies, and safety profile of Narsoplimab.
PDF
246
88
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
